Ipca Laboratories Limited is a leading pharmaceutical company headquartered in Mumbai, India. With over 75 years of experience, the company specializes in the development, manufacture, and marketing of a wide range of pharmaceutical products. Ipca Labs has a strong presence both in the domestic market of India and in several international markets. The company operates in multiple therapeutic segments, including anti-malarials, anti-inflammatory drugs, anti-diabetics, cardiovascular drugs, antibiotics, and more. It offers a diverse portfolio of branded and generic formulations, active pharmaceutical ingredients (APIs), and contract manufacturing services. Ipca Labs is known for its high-quality products, stringent quality control measures, and adherence to global regulatory standards.
- Ipca Laboratories Limited reported Total Income for Q4 FY23 of ₹1,548.02 Crore up from ₹1,303.64 Crore year on year, a growth of 18.7%.
- Total Expenses for Q4 FY23 of ₹1,418.58 Crore up from ₹1,134.09 Crore year on year, a growth of 25.1%.
- Consolidated Net Profit of ₹78.14 Crore, down 40.8% from ₹ 131.98 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹3.02, down from ₹5.13 in the same quarter of the previous year.